EE200200715A - Asendatud kinasoliini derivaadid ja nende kasutamine inhibiitoritena - Google Patents

Asendatud kinasoliini derivaadid ja nende kasutamine inhibiitoritena

Info

Publication number
EE200200715A
EE200200715A EEP200200715A EEP200200715A EE200200715A EE 200200715 A EE200200715 A EE 200200715A EE P200200715 A EEP200200715 A EE P200200715A EE P200200715 A EEP200200715 A EE P200200715A EE 200200715 A EE200200715 A EE 200200715A
Authority
EE
Estonia
Prior art keywords
inhibitors
quinazoline derivatives
substituted quinazoline
substituted
derivatives
Prior art date
Application number
EEP200200715A
Other languages
English (en)
Estonian (et)
Inventor
Mortlock Andrew
Jung Frederic
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of EE200200715A publication Critical patent/EE200200715A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
EEP200200715A 2000-06-28 2001-06-21 Asendatud kinasoliini derivaadid ja nende kasutamine inhibiitoritena EE200200715A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00401842 2000-06-28
PCT/SE2001/001450 WO2002000649A1 (en) 2000-06-28 2001-06-21 Substituted quinazoline derivatives and their use as inhibitors

Publications (1)

Publication Number Publication Date
EE200200715A true EE200200715A (et) 2004-08-16

Family

ID=8173742

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200715A EE200200715A (et) 2000-06-28 2001-06-21 Asendatud kinasoliini derivaadid ja nende kasutamine inhibiitoritena

Country Status (27)

Country Link
US (2) US6919338B2 (xx)
EP (1) EP1299381B1 (xx)
JP (1) JP2004501914A (xx)
KR (1) KR20030014411A (xx)
CN (1) CN1267431C (xx)
AR (1) AR030432A1 (xx)
AT (1) ATE394102T1 (xx)
AU (1) AU2001266505A1 (xx)
BG (1) BG107376A (xx)
BR (1) BR0111754A (xx)
CA (1) CA2412592A1 (xx)
CZ (1) CZ20024120A3 (xx)
DE (1) DE60133897D1 (xx)
EE (1) EE200200715A (xx)
ES (1) ES2305081T3 (xx)
HK (1) HK1053124A1 (xx)
HU (1) HUP0301236A2 (xx)
IL (1) IL153246A0 (xx)
IS (1) IS6656A (xx)
MX (1) MXPA02011974A (xx)
NO (1) NO20026010L (xx)
NZ (1) NZ522696A (xx)
PL (1) PL360439A1 (xx)
RU (1) RU2283311C2 (xx)
SK (1) SK18102002A3 (xx)
WO (1) WO2002000649A1 (xx)
ZA (1) ZA200209412B (xx)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660731B2 (en) * 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
CA2422377C (en) * 2000-09-15 2010-04-13 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) * 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EP1345922B1 (en) * 2000-12-21 2006-05-31 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
ES2333702T3 (es) * 2001-12-24 2010-02-26 Astrazeneca Ab Derivados de quinazolina sustituidos que actuan como unhibidores de cinasas aurora.
ES2437391T3 (es) * 2002-02-06 2014-01-10 Vertex Pharmaceuticals, Inc. Compuestos de heteroarilo útiles como inhibidores de GSK-3
CA2476594C (en) * 2002-03-05 2012-10-09 Transtech Pharma, Inc. Mono-and bicyclic azole derivatives that inhibit the interaction of ligands with rage
ATE468336T1 (de) * 2002-03-15 2010-06-15 Vertex Pharma Azolylaminoazine als proteinkinasehemmer
DE60335099D1 (de) 2002-05-06 2011-01-05 Vertex Pharma Thiadiazole oder oxadiazole und ihre verwendung als jak proteinkinaseinhibitoren
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
CA2491191C (en) 2002-07-15 2014-02-04 Exelixis, Inc. Receptor-type kinase modulators and methods of use
KR20050032105A (ko) * 2002-08-02 2005-04-06 버텍스 파마슈티칼스 인코포레이티드 Gsk-3의 억제제로서 유용한 피라졸 조성물
GB0221245D0 (en) * 2002-09-13 2002-10-23 Astrazeneca Ab Chemical process
KR20050087863A (ko) 2002-12-24 2005-08-31 아스트라제네카 아베 퀴나졸린 화합물
UA86470C2 (ru) * 2002-12-24 2009-04-27 Астразенека Аб Производные фосфонооксихиназолина и их фармацевтическое применение
UA83814C2 (ru) 2002-12-24 2008-08-26 Астразенека Аб Производные фосфонооксихиназолина и их фармацевтическое применение
WO2004072029A2 (en) * 2003-02-06 2004-08-26 Vertex Pharmaceuticals Incorporated Pyrazolopyridazines useful as inhibitors of protein kinases
US7691867B2 (en) 2003-04-16 2010-04-06 Astrazeneca Ab Chemical compounds
AU2004251599A1 (en) * 2003-05-20 2005-01-06 Transtech Pharma, Inc. Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
ES2308182T3 (es) * 2003-06-02 2008-12-01 Astrazeneca Ab Derivadosde (3-((quinazolin-4-il)amino)-1h-pirazol-1-il)acetamida y compuestos relacionados como inhibidores de quinasas aurora para el tratamiento de enfermedades proliferativas tales como el cancer.
TW200505452A (en) * 2003-06-17 2005-02-16 Astrazeneca Ab Chemical compounds
GB0320793D0 (en) * 2003-09-05 2003-10-08 Astrazeneca Ab Chemical process
ATE517091T1 (de) 2003-09-26 2011-08-15 Exelixis Inc C-met-modulatoren und verwendungsverfahren
US20080051414A1 (en) * 2003-10-14 2008-02-28 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
EP1678166B1 (en) * 2003-10-14 2009-07-29 The Arizona Board of Regents on Behalf of the University of Arizona Protein kinase inhibitors
US20090099165A1 (en) * 2003-10-14 2009-04-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
US20090143399A1 (en) * 2003-10-14 2009-06-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
AU2004285052A1 (en) * 2003-10-31 2005-05-12 Neurogen Corporation 4-amino (AZA) quinoline derivatives as capsaicin receptor agonists
JP2007513184A (ja) * 2003-12-04 2007-05-24 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼのインヒビターとして有用なキノキサリン
JP2007514759A (ja) * 2003-12-19 2007-06-07 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
WO2005066152A1 (en) * 2003-12-30 2005-07-21 The Brigham And Women's Hospital, Inc. Thiophene derivatives for up-regulating hla-dm activity
JPWO2005090332A1 (ja) * 2004-03-23 2008-01-31 萬有製薬株式会社 置換キナゾリン又はピリドピリミジン誘導体
WO2005105788A1 (en) * 2004-04-23 2005-11-10 Takeda San Diego, Inc. Indole derivatives and use thereof as kinase inhibitors
WO2006023931A2 (en) * 2004-08-18 2006-03-02 Takeda San Diego, Inc. Kinase inhibitors
US20090036485A1 (en) * 2004-10-12 2009-02-05 Frederic Henri Jung Quinoline derivatives
CA2581516C (en) * 2004-10-12 2013-06-11 Astrazeneca Ab Quinazoline derivatives
US7713973B2 (en) 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
CN1854130B (zh) * 2005-04-15 2011-04-20 中国医学科学院药物研究所 喹唑啉衍生物、及其制法和药物组合物与用途
GB0509227D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
GB0510963D0 (en) * 2005-05-28 2005-07-06 Astrazeneca Ab Chemical compounds
WO2007022384A2 (en) * 2005-08-18 2007-02-22 Vertex Pharmaceuticals Incorporated Pyrazine kinase inhibitors
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
CN103145702A (zh) * 2005-11-03 2013-06-12 顶点医药品公司 用作激酶抑制剂的氨基嘧啶
EP1785420A1 (en) * 2005-11-14 2007-05-16 4Sc Ag Thiazole analogues and uses thereof
DK1984353T3 (en) 2006-01-23 2016-03-14 Amgen Inc Aurorakinasemodulatorer and method of use
US7560551B2 (en) 2006-01-23 2009-07-14 Amgen Inc. Aurora kinase modulators and method of use
US7868177B2 (en) * 2006-02-24 2011-01-11 Amgen Inc. Multi-cyclic compounds and method of use
WO2007099323A2 (en) * 2006-03-02 2007-09-07 Astrazeneca Ab Quinoline derivatives
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
WO2007113005A2 (en) * 2006-04-03 2007-10-11 European Molecular Biology Laboratory (Embl) 2-substituted 3-aminosulfonyl-thiophene derivatives as aurora kinase inhibitors
GEP20135728B (en) 2006-10-09 2013-01-25 Takeda Pharmaceuticals Co Kinase inhibitors
US8883790B2 (en) 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
US8236823B2 (en) 2006-10-27 2012-08-07 Amgen Inc. Multi-cyclic compounds and methods of use
US20080207632A1 (en) * 2006-10-31 2008-08-28 Supergen, Inc. Protein kinase inhibitors
NZ576750A (en) * 2006-11-02 2012-01-12 Vertex Pharma Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases
DE602007007985D1 (de) * 2006-12-19 2010-09-02 Vertex Pharma Als inhibitoren von proteinkinasen geeignete aminopyrimidine
AU2008226461A1 (en) * 2007-03-09 2008-09-18 Vertex Pharmaceuticals Incorporated Aminopyridines useful as inhibitors of protein kinases
CA2680029A1 (en) * 2007-03-09 2008-09-18 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
WO2008112642A1 (en) * 2007-03-09 2008-09-18 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
AU2008236670B2 (en) 2007-04-05 2011-12-01 Amgen Inc. Aurora kinase modulators and method of use
AU2008240313A1 (en) 2007-04-13 2008-10-23 Aj Park Aminopyrimidines useful as kinase inhibitors
EP2152694A2 (en) 2007-05-02 2010-02-17 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
CN101801959A (zh) * 2007-05-02 2010-08-11 沃泰克斯药物股份有限公司 可用作激酶抑制剂的氨基嘧啶类化合物
CN101679387A (zh) * 2007-05-02 2010-03-24 沃泰克斯药物股份有限公司 可用作激酶抑制剂的氨基嘧啶类化合物
GB0709031D0 (en) 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
AU2008257044A1 (en) * 2007-05-24 2008-12-04 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
WO2008156726A1 (en) * 2007-06-20 2008-12-24 Merck & Co., Inc. Inhibitors of janus kinases
CN101687821A (zh) * 2007-06-21 2010-03-31 Irm责任有限公司 蛋白激酶抑制剂及其使用方法
WO2009018415A1 (en) 2007-07-31 2009-02-05 Vertex Pharmaceuticals Incorporated Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
DE102008015033A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung
DE102008015032A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte Pyrazolamide und ihre Verwendung
ES2413806T3 (es) * 2008-03-20 2013-07-17 Amgen Inc. Moduladores de la aurora cinasa y método de uso
US9126935B2 (en) 2008-08-14 2015-09-08 Amgen Inc. Aurora kinase modulators and methods of use
MX2011002312A (es) * 2008-09-03 2011-04-26 Vertex Pharma Co-cristales y formulaciones farmaceuticas que comprenden los mismos.
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
EP3623374B1 (en) 2008-12-03 2021-09-08 The Scripps Research Institute Stem cell cultures
DE102008062863A1 (de) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituierte (Thiophenyl-carbonyl)imidazolidinone und ihre Verwendung
DE102008062878A1 (de) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituierte Furancarboxamide und ihre Verwendung
TW202241853A (zh) 2009-01-16 2022-11-01 美商艾克塞里克斯公司 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途
KR101699991B1 (ko) * 2009-02-11 2017-01-26 메르크 파텐트 게엠베하 신규의 아미노 아자헤테로시클릭 카르복사미드
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US8580833B2 (en) 2009-09-30 2013-11-12 Transtech Pharma, Inc. Substituted imidazole derivatives and methods of use thereof
CN102971313A (zh) 2010-04-14 2013-03-13 百时美施贵宝公司 新颖的葡糖激酶激活剂及其使用方法
US9090633B2 (en) 2010-11-18 2015-07-28 Kasina Laila Innova Pharmaceuticals Private Limited Substituted 4-(arylamino) selenophenopyrimidine compounds and methods of use thereof
EP2640392B1 (en) * 2010-11-18 2015-01-07 Kasina Laila Innova Pharmaceuticals Private Ltd. Substituted 4-(selenophen-2(or 3)-ylamino)pyrimidine compounds and methods of use thereof
US8785459B2 (en) * 2011-12-27 2014-07-22 Development Center For Biotechnology Quinazoline compounds as kinase inhibitors
GB201202027D0 (en) 2012-02-06 2012-03-21 Sareum Ltd Pharmaceutical compounds
DK3040336T3 (da) 2012-03-02 2020-06-22 Sareum Ltd Forbindelser til brug i behandling af TYK2 Kinase-medierede tilstande
CN103788085B (zh) * 2012-10-31 2016-09-07 复旦大学 2-(喹唑啉-4-氨基)-5-噻唑甲酰胺类衍生物及其生物药物用途
CN104098551B (zh) * 2013-04-03 2019-03-22 广东东阳光药业有限公司 作为欧若拉激酶抑制剂的取代喹唑啉类衍生物
MX370490B (es) 2013-09-16 2019-12-16 Astrazeneca Ab Nanopartículas poliméricas terapéuticas y métodos para su elaboración y uso.
US20190112317A1 (en) 2015-10-05 2019-04-18 The Trustees Of Columbia University In The City Of New York Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
GB201617871D0 (en) 2016-10-21 2016-12-07 Sareum Limited Pharmaceutical compounds
AR112027A1 (es) * 2017-06-15 2019-09-11 Biocryst Pharm Inc Inhibidores de alk 2 quinasa que contienen imidazol
CN114302876A (zh) * 2019-09-06 2022-04-08 英夫拉索姆有限公司 Nlrp3抑制剂
CN110746398A (zh) * 2019-10-18 2020-02-04 刘沛友 4-杂环取代喹唑啉类衍生物及其制备方法和用途
CN111574473A (zh) * 2020-06-04 2020-08-25 宁夏农林科学院农业资源与环境研究所(宁夏土壤与植物营养重点实验室) 一种氨基噻唑类化合物的合成方法
CN113311166B (zh) * 2021-04-28 2022-10-28 新疆农垦科学院 一种用于绵羊早期妊娠诊断的蛋白生物标志物及其用于绵羊早期妊娠检测的方法
CN115557601A (zh) * 2022-11-08 2023-01-03 成都理工大学 生物质微球及其制备方法与应用、生物反应器、地下井

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870725A (en) * 1971-03-30 1975-03-11 Lilly Industries Ltd Nitrothiazole derivatives
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
ES2108120T3 (es) 1991-05-10 1997-12-16 Rhone Poulenc Rorer Int Compuestos bis arilicos y heteroarilicos mono- y biciclicos que inhiben tirosina quinasa receptora de egf y/o pdgf.
NZ243082A (en) * 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
IL117620A0 (en) * 1995-03-27 1996-07-23 Fujisawa Pharmaceutical Co Heterocyclic compounds processes for the preparation thereof and pharmaceutical compositions containing the same
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
US6716575B2 (en) * 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
TW436485B (en) * 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
ES2241324T3 (es) * 1998-10-08 2005-10-16 Astrazeneca Ab Derivados de quinazolina.
GB9922171D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds

Also Published As

Publication number Publication date
EP1299381B1 (en) 2008-05-07
CN1267431C (zh) 2006-08-02
JP2004501914A (ja) 2004-01-22
SK18102002A3 (sk) 2003-07-01
IS6656A (is) 2002-12-17
MXPA02011974A (es) 2004-09-06
US20060046987A1 (en) 2006-03-02
BG107376A (bg) 2003-09-30
CN1496364A (zh) 2004-05-12
CZ20024120A3 (cs) 2003-03-12
ES2305081T3 (es) 2008-11-01
KR20030014411A (ko) 2003-02-17
PL360439A1 (en) 2004-09-06
IL153246A0 (en) 2003-07-06
BR0111754A (pt) 2003-04-29
NZ522696A (en) 2004-08-27
HK1053124A1 (en) 2003-10-10
NO20026010D0 (no) 2002-12-13
WO2002000649A1 (en) 2002-01-03
AU2001266505A1 (en) 2002-01-08
CA2412592A1 (en) 2002-01-03
RU2283311C2 (ru) 2006-09-10
US20030187002A1 (en) 2003-10-02
WO2002000649A9 (en) 2007-09-20
ZA200209412B (en) 2004-02-19
ATE394102T1 (de) 2008-05-15
AR030432A1 (es) 2003-08-20
US6919338B2 (en) 2005-07-19
NO20026010L (no) 2002-12-13
EP1299381A1 (en) 2003-04-09
HUP0301236A2 (hu) 2003-10-28
DE60133897D1 (de) 2008-06-19

Similar Documents

Publication Publication Date Title
EE200200715A (et) Asendatud kinasoliini derivaadid ja nende kasutamine inhibiitoritena
EE200200576A (et) Oksasooli derivaadid ja nende kasutamine türosiini kinaasi inhibiitoritena
EE200300459A (et) Uued spirotritsüklilised derivaadid ja nende kasutamine fosfodiesteraas-7 inhibiitoritena
EE200100373A (et) Bensoheterotsüklid ja nende kasutamine MEK inhibiitoritena
EE200300085A (et) Pürasooli derivaadid ja nende kasutamine proteiini kinaasi inhibiitoritena
EE200300071A (et) Kinasoliini derivaadid
CY2012026I2 (el) Παραγωγα κουιναζολινης ως αναστολεις vegf
EE200200251A (et) Uued N-asabitsükloamiidi derivaadid ja nende kasutamine
DE60103974D1 (de) Gyrase-inhibitoren und ihre verwendung
EE200200550A (et) Karbamaatsed kaspaasi inhibiitorid ja nende kasutamine
DK1000039T3 (da) Substituerede quinazolinderivater og anvendelse deraf som tyrosinkinaseinhibitorer
EE200200626A (et) Antraniilamiidid ja nende kasutamine ravimitena
ATE540013T1 (de) Naphthalinderivate
AR028575A1 (es) Derivados de pirrolopiridinona utiles como inhibidores de fosfodiesterasa
NO20025510L (no) Dibenzoazulen-derivater samt anvendelse derav
EE200100371A (et) Amidinobensüülamiini derivaadid ja nende kasutamine trombiini inhibiitoritena
EE200300491A (et) 6-asendis asendatud indolinoonid ja nende kasutamine kinaas-inhibiitoritena
FI20001715A0 (fi) Rankoihin liittyvät järjestelyt ja menetelmät
AR028068A1 (es) Nuevos derivados de 1,1-dioxotiocromano y su uso como inhibidores de trombina
DE60117096D1 (de) Dihydroindol- und tetrahydrochinolinderivate
ATE305460T1 (de) 2-aminothiazolinderivate und ihre verwendung als no-synthase inhibitoren
DE60101245D1 (de) Beschichtungszusammensetzung und ihre Verwendung
DK1392670T3 (da) Substituerede C-furan-2-yl-methylamin- og C-thiophen-2-yl-methylamin-derivater
ATE347544T1 (de) Substituierte phenylcyclohexancarbonsäureamide und ihre verwendung
EE200200611A (et) Antihüpertensiivsed ained ja kasutamine